These 5 Potential Catalysts Put NYSE American Biotech Profile (MAIA) All Over My Radar

This is your wake-up call.

Don’t Want These Anymore? Unsubscribe Here! *Sponsored These 5 Potential Catalysts Put NYSE American Biotech Profile (MAIA) All Over My Radar July 9th Greetings Readers, This is your wake-up call. Right now, we’re dropping a report that could send shockwaves through the biotech sector—and you do NOT want to be caught off guard. We’re talking about a company profile with a relatively low float, meaning the potential for volatility could be heightened. Plus, an analyst is buzzing, and the target they’ve set? Let’s just say it’s not double, not triple, but over 5X current chart levels. This is the kind of under-the-radar idea that doesn’t come around often. Listen up. Attention is being drawn to a significant development in the treatment of advanced non-small cell lung cancer. A novel therapeutic approach, recently featured at a leading international oncology conference, has shown promising results in patients unresponsive to current immunotherapies. This innovative method targets telomeres within cancer cells, resulting in substantial tumor regression and heightened immune activity. Clinical findings are attracting recognition from experts and may signal a shift in the management of resistant lung cancer cases. Ongoing clinical trials will further clarify the potential of this therapy, making it an area worth monitoring closely as new data emerges. Furthermore, when I brought this one to your attention back in 2024, it erupted, running approximately 275+% in a few month span. That's why this NYSE American biotech idea is topping my watchlist: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Could Be In Full Force Based On MAIA's Low Float. #3. MAIA Biotechnology Announced A New PR As Patient's Tumor Size Decreases By At Least 30%. #4. MAIA Biotechnology Enters Into A Key Supply Agreement With Roche For Future Studies. #5. MAIA Welcomes Experts To Board, Strengthening Oncology Innovation Leadership Team. But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development MAIA is currently advancing THIO in a Phase 2 clinical study in Non-Small Cell Lung Cancer (NSCLC). This is the first study to test THIO’s immune system activation followed by administration of the checkpoint inhibitor cemiplimab, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of THIO administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels. Last month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Tuesday's closing valuation, that provides MAIA with upside potential well over 600%! Check out some key report highlights: Conclusion. Roche becomes the third pharmaceutical company to make a supply agreement with MAIA to test a checkpoint inhibitor in combination with THIO. We believe this shows that potential partners have noticed the data showing improved overall survival (OS), progression free survival (PFS), and the side effect profile. Clinical data from the three of the eight approved checkpoint inhibitors could make bidding for a marketing partnership more competitive. We are reiterating our Outperform rating and $14 price target. ----- #2. MAIA Potential Catalyst - Volatility Could Be In Full Force Based On MAIA's Low Float. According to info from the Yahoo Finance website, MAIA has a relatively low float. The website reports this profile to have roughly 25.65Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could even more positive company news in mid-2025 provide a breakout spark? ----- #3. MAIA Potential Catalyst - MAIA Biotechnology Announced A New PR As Patient's Tumor Size Decreases By At Least 30%. MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial CHICAGO, June 05, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. "The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor," said MAIA Chairman and CEO Vlad Vitoc, M.D. "We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients." THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.1 ... Read the full article here. ----- #4. MAIA Potential Catalyst - MAIA Biotechnology Enters Into A Key Supply Agreement With Roche For Future Studies. MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments CHICAGO, June 18, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers. "In preclinical studies, ateganosine was found to be highly synergistic and effective in combination with Roche’s anti-PD-L1 agent atezolizumab," said MAIA Chairman and CEO Vlad Vitoc, M.D. "We are pleased to partner with world-renowned Roche and we look forward to further strengthening our mission to find safe and effective cancer treatments." Read the full article here. ----- #5. MAIA Potential Catalyst - MAIA Welcomes Experts To Board, Strengthening Oncology Innovation Leadership Team. MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway CHICAGO, June 24, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA’s lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST). "Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy," said MAIA Chairman and CEO Vlad Vitoc, M.D. "They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC." "By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial," Dr. Vitoc added. ... Read the full article here. ----- MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Could Be In Full Force Based On MAIA's Low Float. #3. MAIA Biotechnology Announced A New PR As Patient's Tumor Size Decreases By At Least 30%. #4. MAIA Biotechnology Enters Into A Key Supply Agreement With Roche For Future Studies. #5. MAIA Welcomes Experts To Board, Strengthening Oncology Innovation Leadership Team. ----- Coverage is officially reinitiated on (NYSE American: MAIA). When updates are available, I'll get them out quickly. Talk soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice